Prioritising the application of genomic medicine
The clinical translation of genomic sequencing is hampered by the limited information available to guide investment into those areas where genomics is well placed to deliver improved health and economic outcomes. To date, genomic medicine has achieved its greatest successes through applications to diseases that have a high genotype-phenotype correlation and high penetrance, with a near certainty that the individual will develop the condition in the presence of the genotype. It has been anticipated that genomics will play an important role in promoting population health by targeting at-risk individuals and reducing the incidence of highly prevalent, costly, complex diseases, with potential applications across screening, prevention, and treatment decisions. However, where primary or secondary prevention requires behavioural changes, there is currently very little evidence to support reduction in disease incidence. A better understanding of the relationship between genomic variation and complex diseases will be necessary before effective genomic risk identification and management of the risk of complex diseases in healthy individuals can be carried out in clinical practice. Our recommended approach is that priority for genomic testing should focus on diseases where there is strong genotype-phenotype correlation, high or certain penetrance, the effects of the disease are serious and near-term, there is the potential for prevention and/or treatment, and the net costs incurred are acceptable for the health gains achieved.
|ISBN||2056-7944 (Electronic) 2056-7944 (Linking)|
|Authors||Doble, B.; Schofield, D. J.; Roscioli, T.; Mattick, J. S.|
|Responsible Garvan Author|
|Publisher Name||NPJ Genomic Medicine|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/29263844|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/14487|